The Division of Medical Oncology plays a pivotal role in coordinating patient care, clinical research and medical education at Hartford Hospital. As the general US population continues to age, the number of new cancer cases is projected to increase by 50% over the next 20 years.

Hartford Hospital remains committed to providing stateof-the-art treatments to participation in multi-institutional clinical trials through the Gynecologic Oncology Group (GOG), through the National Surgical Adjuvant Breast and Bowel Project (NSABP), and the Cancer and Leukemia Group B (CALGB). 
 
On the national level, there has been considerable interest and attention drawn to positive studies showing a significant improvement in survival in patients with early stage lung cancer treated with adjuvant chemotherapy following surgical removal of their tumors. 

This is an exciting time in the evolution of medical oncology as a specialty. Many less toxic, more targeted therapies are now available for patient with a wide range of tumors. Clinical studies that are currently in progress should become available for many of the more common solid tumors within the next several years. We are very optimistic that the results of basic research will give far more options for our patients.

As our patient population continues to increase each year, we anticipate expanding our division in order to provide state-of-the-art cancer care in Hartford and the surrounding communities.